Lexaria Bioscience Corp. (LEXX)
2.88
-0.21
(-6.80%)
USD |
NASDAQ |
Oct 02, 16:00
2.77
-0.11
(-3.82%)
After-Hours: 20:00
Lexaria Bioscience Enterprise Value : 0.8348M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 0.8348M |
| October 01, 2026 | 1.182M |
| September 30, 2026 | 1.281M |
| September 29, 2026 | 1.248M |
| September 28, 2026 | 1.405M |
| September 25, 2026 | 1.496M |
| September 24, 2026 | 1.644M |
| September 23, 2026 | 1.421M |
| September 22, 2026 | 1.397M |
| September 21, 2026 | 1.735M |
| September 18, 2026 | 1.430M |
| September 17, 2026 | 1.512M |
| September 16, 2026 | 1.190M |
| September 15, 2026 | 1.380M |
| September 14, 2026 | 1.942M |
| September 11, 2026 | 2.636M |
| September 10, 2026 | 2.768M |
| September 09, 2026 | 6.982M |
| September 08, 2026 | 11.56M |
| September 04, 2026 | 19.46M |
| September 03, 2026 | 16.43M |
| September 02, 2026 | 17.90M |
| September 01, 2026 | 16.69M |
| August 31, 2026 | 14.72M |
| August 28, 2026 | 13.18M |
| Date | Value |
|---|---|
| August 27, 2026 | 15.38M |
| August 26, 2026 | 14.32M |
| August 25, 2026 | 15.24M |
| August 24, 2026 | 13.49M |
| August 21, 2026 | 14.11M |
| August 20, 2026 | 14.70M |
| August 19, 2026 | 15.10M |
| August 18, 2026 | 15.11M |
| August 17, 2026 | 13.13M |
| August 14, 2026 | 11.01M |
| August 13, 2026 | 9.461M |
| August 12, 2026 | 6.189M |
| August 11, 2026 | 5.644M |
| August 10, 2026 | 5.148M |
| August 07, 2026 | 4.784M |
| August 06, 2026 | 4.90M |
| August 05, 2026 | 5.445M |
| August 04, 2026 | 5.363M |
| August 03, 2026 | 3.925M |
| July 31, 2026 | 5.768M |
| July 30, 2026 | 5.899M |
| July 29, 2026 | 9.213M |
| July 28, 2026 | 9.463M |
| July 27, 2026 | 9.002M |
| July 24, 2026 | 9.932M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Target Group, Inc. (Canada) | 11.59M |
| InMed Pharmaceuticals, Inc. | 4.867M |
| XORTX Therapeutics, Inc. | 1.973M |
| NervGen Pharma Corp. | 128.24M |
| Milestone Pharmaceuticals, Inc. | 72.03M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.993M |
| Total Expenses (Quarterly) | 1.991M |
| EPS Diluted (Quarterly) | -1.204 |
| Earnings Yield | -183.4% |
| Normalized Earnings Yield | -178.78 |